Structural requirements for drug inhibition of the liver specific human organic cation transport protein 1.
about
Role of the plasma membrane transporter of organic cations OCT1 and its genetic variants in modern liver pharmacologyHepatocyte nuclear factor 1 regulates the expression of the organic cation transporter 1 via binding to an evolutionary conserved region in intron 1 of the OCT1 geneProton pump inhibitors inhibit metformin uptake by organic cation transporters (OCTs)Inhibition of Human Drug Transporter Activities by the Pyrethroid Pesticides Allethrin and Tetramethrin.Membrane transporters in drug developmentMembrane transporters as mediators of Cisplatin effects and side effects.Expression of organic cation transporters OCT1 (SLC22A1) and OCT3 (SLC22A3) is affected by genetic factors and cholestasis in human liver.Discovery of potent, selective multidrug and toxin extrusion transporter 1 (MATE1, SLC47A1) inhibitors through prescription drug profiling and computational modelingComparison of human solute carriersProfiling of a prescription drug library for potential renal drug-drug interactions mediated by the organic cation transporter 2Fluorescence-based assays for the assessment of drug interaction with the human transporters OATP1B1 and OATP1B3Potent inhibitors of human organic anion transporters 1 and 3 from clinical drug libraries: discovery and molecular characterizationVerapamil decreases the glucose-lowering effect of metformin in healthy volunteersInteractions of tyrosine kinase inhibitors with organic cation transporters and multidrug and toxic compound extrusion proteinsSelective regulation of cardiac organic cation transporter novel type 2 (OCTN2) in dilated cardiomyopathyAssociation of Organic Cation Transporter 1 With Intolerance to Metformin in Type 2 Diabetes: A GoDARTS Study.Molecular determinants of ligand selectivity for the human multidrug and toxin extruder proteins MATE1 and MATE2-K.Role of a Hydrophobic Pocket in Polyamine Interactions with the Polyspecific Organic Cation Transporter OCT3Atenolol Renal Secretion Is Mediated by Human Organic Cation Transporter 2 and Multidrug and Toxin Extrusion Proteins.Organic cation transporter 1 (OCT1) is involved in pentamidine transport at the human and mouse blood-brain barrier (BBB).The human organic cation transporter OCT1 mediates high affinity uptake of the anticancer drug daunorubicinPolyamine transport by the polyspecific organic cation transporters OCT1, OCT2, and OCT3Substrate-dependent ligand inhibition of the human organic cation transporter OCT2.Clinical pharmacokinetics of fexofenadine enantiomers.Multiple mechanisms of ligand interaction with the human organic cation transporter, OCT2Renal clearance in drug discovery and development: molecular descriptors, drug transporters and disease state.Transporters that translocate nucleosides and structural similar drugs: structural requirements for substrate recognition.Renal transport of organic anions and cations.Transporter-mediated drug-drug interactions with oral antidiabetic drugs.Transporter-Mediated Disposition of Opioids: Implications for Clinical Drug Interactions.OCT1 and imatinib transport in CML: is it clinically relevant?Transporter assays as useful in vitro tools in drug discovery and development.Computational modeling to predict the functions and impact of drug transporters.Predicting Clearance Mechanism in Drug Discovery: Extended Clearance Classification System (ECCS).Expression of organic cation transporter 1 (OCT1): unique patterns of indirect regulation by nuclear receptors and hepatospecific gene regulation.The poorly membrane permeable antipsychotic drugs amisulpride and sulpiride are substrates of the organic cation transporters from the SLC22 family.The mitochondrial fluorescent dye rhodamine 123 is a high-affinity substrate for organic cation transporters (OCTs) 1 and 2.An HPLC-UV method for the measurement of permeability of marker drugs in the Caco-2 cell assay.Lack of Influence of Substrate on Ligand Interaction with the Human Multidrug and Toxin Extruder, MATE1.Genotype-dependent effects of inhibitors of the organic cation transporter, OCT1: predictions of metformin interactions.
P2860
Q27026858-03920F60-84BC-40BC-800D-C2D606E8C8E2Q28296115-FF6A23AA-979D-4D9F-809A-9DDD69D542E6Q28479037-DCF2C037-0F69-4167-95A6-D8141086C1EFQ28818842-BDA8EE21-48A9-4BEE-923D-3A7F5C405BCBQ29616802-D9D25F94-1AF6-42FD-B13E-50E7FC5378CFQ30446860-CE613822-D3ED-43C4-85AA-DDE404E00D2EQ33480591-45B973EE-144D-4138-9958-62C5EFAA03EAQ33799288-B0578AE3-9412-4989-B091-EC8B2FA9F334Q33836276-95752E2C-214C-4E81-8512-B4991CE29D14Q33907033-30E4278B-C268-42A0-B890-212225DD1DA0Q34058706-27C42651-7A98-4745-86C1-0BC161E5092FQ34413813-0F6D7949-B0F4-410F-BACC-98D176E77BB5Q34635590-6BF08998-7F12-4BBC-9CD4-EFF74AE077F9Q34714353-7BA55F45-90B7-4978-B15F-FF09B4982D96Q35071386-E4779F9A-4497-4697-95CF-AE5AF063BA7FQ35675566-AADF1054-C300-420E-9EF8-D7C7DC7F6FB8Q35996683-7811D08C-B13E-4797-86C7-B51228C1B88AQ36282875-4DB7D49A-CDDE-4DB0-A291-EAEB4FB12856Q36316489-9531C678-005F-43F4-AD4E-31DC203F7EE1Q36329959-062D14AB-79E1-4AB5-B940-9AAE18B97A7AQ36564944-BB2D83F1-59DC-48C1-83E2-0FA16DD11077Q36784291-9D0ECD17-F8B6-4E96-A6BE-E07DB05444D2Q37027034-195A4212-8B7F-4A08-8A28-BECD2FE6AD48Q37641373-E67AB468-20FA-4704-8B64-D584F4A59F0DQ37676172-E98752E8-7EFF-4AC7-A832-71CAE4D5911AQ37740151-12C59805-0A18-4ABC-8FF9-C9381B9AA5FDQ37834510-14822E69-C6EF-4652-BD2D-6689A48E1691Q38111725-3CB1E444-B219-4A9C-981E-A63EE055AE0EQ38168993-ED07245A-1DD2-49E3-9D35-624F0A1D633EQ38478413-135B2B49-9BFB-4F2F-BA28-9666D004F7E2Q38540022-FE03EBE3-86E9-4C4E-94C2-90FC8B0AA28DQ38619057-A59592C0-9A6E-4435-AD84-A2E8A86C0A00Q38715008-F7FB6052-9089-4739-A3DD-0D07A001E796Q38855314-16A66DCC-3C25-42BE-9DA5-AAF2559414AAQ38859468-18D5F77C-4EE0-4F7A-A28E-31980DD5AAC1Q38962943-722613D0-60F3-4A18-9153-329DA6287889Q39293014-AB2D496C-CDFD-4D35-952E-F093D46083CAQ39541224-89AB8BC2-4201-4656-9A83-D4EB71BD3E17Q39599846-8F127E00-1A4C-4E6C-A88F-A045B9D83DCFQ39689968-5A4AF6BA-13E7-416A-8CFB-A562B4059C75
P2860
Structural requirements for drug inhibition of the liver specific human organic cation transport protein 1.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
2008年论文
@zh
2008年论文
@zh-cn
name
Structural requirements for dr ...... ic cation transport protein 1.
@en
Structural requirements for dr ...... ic cation transport protein 1.
@nl
type
label
Structural requirements for dr ...... ic cation transport protein 1.
@en
Structural requirements for dr ...... ic cation transport protein 1.
@nl
prefLabel
Structural requirements for dr ...... ic cation transport protein 1.
@en
Structural requirements for dr ...... ic cation transport protein 1.
@nl
P2093
P50
P921
P356
P1476
Structural requirements for dr ...... nic cation transport protein 1
@en
P2093
Gustav Ahlin
Jenny M Pedersen
Johan Karlsson
Lena Gustavsson
Per Artursson
Rolf Larsson
P304
P356
10.1021/JM8003152
P407
P577
2008-09-13T00:00:00Z